 Patients should
be started on dual antiplatelet therapy with aspirin (325
mg) and clopidogrel (75 mg) or ticlopidine (250 mg). No
randomized trial has yet compared CAS performed with
dual-antiplatelet therapy vs aspirin alone. However, the
published periprocedural stroke, MI, and death rates in all
recent clinical trials have been achieved with this combination therapy.9,10